en · de · es
sr9009-notes.peptides1004.com › Wiki › Background And Receptor Mechanism — What the Evidence Shows

Background And Receptor Mechanism — What the Evidence Shows

By Editorial Desk · published 2025-12-16 · last reviewed 2026-01-02 · Wiki

circadian rhythm is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-01-02. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

Mechanism and Preclinical Findings

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic small moleculeStudied as a REV-ERB agonist
Molecular formulaC20H24ClN3O4SReported for the neutral compound
AppearanceOff-white to pale yellow solidTypical research-grade material
SolubilitySparingly soluble in waterSoluble in solvents such as DMSO
Common synonymsSR9009; StenabolicStenabolic is an informal alias

Analytical and Handling Considerations

Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.

SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.

Related pages on this site

Regulation, Testing, and Storage

Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.

Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.

Supporting material

=== Netherlands === In the Netherlands, all parts of Papaver somniferum after harvesting (except for the seeds) are illegal by law, as they are Listed as drugs in the Opium Law. Because of use for decorative purposes, the trade in, and possession of dried Papaver somniferum is not actively prosecuted. Trade in, or possession of dried Papaver somniferum with the intention of drug use can be prosecuted. The dried seed pod of Papaver somniferum is easily obtainable as it is commonly available for decorative use. Many varieties, strains, and cultivars of Papaver somniferum are in existence, and the alkaloid content can vary significantly.

== Assembly methods == A persistent problem within tissue engineering is mass transport limitations. Engineered tissues generally lack an initial blood supply, thus making it difficult for any implanted cells to obtain sufficient oxygen and nutrients to survive, or function properly.

Instant coffee is a beverage derived from processed brewed coffee beans that is quickly prepared by adding hot water or milk to powdered solid coffee extracts. Instant coffee solids in powdered or crystallized form (also called soluble coffee, coffee extract, coffee crystals, coffee powder, or powdered coffee, and often sold as "instant coffee") refers to dehydrated and packaged solids used to make the instant coffee beverage. The product was invented in 1890 in Invercargill, Southland, New Zealand by David Strang. Instant coffee solids are commercially prepared by either freeze-drying or spray drying coffee beverage. Instant coffee is also manufactured in a concentrated liquid form. Instant coffee has advantages over coffee brewed from ground coffee beans including speed of preparation (instant coffee dissolves quickly in hot water), lower shipping weight and volume than beans or ground coffee for the same amount of beverage, and long shelf life—though instant coffee can spoil if not kept dry. However, the beverage made from ground coffee is considered to have superior quality and taste. Instant coffee also reduces cleanup since there are no coffee grounds. At least one study has found that instant coffee has a lower environmental footprint than drip filter coffee and capsule espresso coffee, on a prepared beverage basis, disregarding quality and appeal of the beverage produced. The global instant coffee market was valued at US$4.16 Billion in 2026.

Sources: en.wikipedia.org

Supporting material

In MASS, the sample is spun at several kilohertz around an axis that makes the so-called magic angle θm (which is ~54.74°, where 3cos2θm-1 = 0) with respect to the direction of the static magnetic field B0; as a result of such magic angle sample spinning, the broad chemical shift anisotropy bands are averaged to their corresponding average (isotropic) chemical shift values. Correct alignment of the sample rotation axis as close as possible to θm is essential for cancelling out the chemical-shift anisotropy broadening. There are different angles for the sample spinning relative to the applied field for the averaging of electric quadrupole interactions and paramagnetic interactions, correspondingly ~30.6° and ~70.1°. In amorphous materials, residual line broadening remains since each segment is in a slightly different environment, therefore exhibiting a slightly different NMR frequency. Line broadening or splitting by dipolar or J-couplings to nearby 1H nuclei is usually removed by radio-frequency pulses applied at the 1H frequency during signal detection. The concept of cross polarization developed by Sven Hartmann and Erwin Hahn was utilized in transferring magnetization from protons to less sensitive nuclei by M.G. Gibby, Alex Pines and John S. Waugh. Then, Jake Schaefer and Ed Stejskal demonstrated the powerful use of cross polarization under MAS conditions (CP-MAS) and proton decoupling, which is now routinely employed to measure high-resolution spectra of low-abundance and low-sensitivity nuclei, such as carbon-13, silicon-29, or nitrogen-15, in solids.

== Risk factors == Risk factors for thromboembolism, the major cause of arterial embolism, include disturbed blood flow (such as in atrial fibrillation and mitral stenosis), injury or damage to an artery wall, and hypercoagulability (such as increased platelet count). Mitral stenosis poses a high risk of forming emboli which may travel to the brain and cause stroke. Endocarditis increases the risk for thromboembolism, by a mixture of the factors above. Atherosclerosis in the aorta and other large blood vessels is a common risk factor, both for thromboembolism and cholesterol embolism. The legs and feet are major impact sites for these types. Thus, risk factors for atherosclerosis are risk factors for arterial embolisation as well:

The new 19th district, then as now, encompasses much of West Texas including Lubbock and Abilene along with Big Spring. The incumbent is Republican Jodey Arrington, who was re-elected with 80.7% of the vote in 2024. Arrington is not seeking reelection to a sixth term in the heavily Republican district, which gave 75.3% of the vote to Donald Trump and 73% to Ted Cruz in 2024, and is a majority White district with a voting age population that is 34.7% Hispanic.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.

Is SR9009 a SARM?

No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.

What human data exist for SR9009?

Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.

What is SR9009?

It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.

Network